Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

The race for pharmaceutical dominance often centers on chronic disease management. For investors, deciding between Novo Nordisk (NYSE:NVO) and Regeneron Pharmaceuticals (NASDAQ:REGN) requires a close look at their unique market strengths.

Novo Nordisk focuses heavily on metabolic disorders, particularly diabetes and weight loss, where it holds a massive global share. Regeneron leverages its proprietary technologies to develop treatments for eye diseases, cancer, and inflammatory conditions. Comparing these two giants reveals different approaches to growth and risk.

The case for Novo Nordisk

Novo Nordisk operates as a specialized leader among pharmaceutical stocks focusing on chronic disease care. Its primary focus remains on diabetes and obesity, where it provides essential medicines like insulin and GLP-1 treatments to patients in roughly 170 countries. Its latest annual report, filed for 2025, noted a workforce of approximately 68,800 people dedicated to these therapeutic areas. While major customers are not specifically disclosed in SEC filings, the company relies on a diverse base of healthcare providers and distributors globally.

In FY 2025, revenue reached nearly $47.7 billion, representing a 6.4% increase over the previous year. This growth follows a significant expansion in its obesity care portfolio during prior fiscal periods. The firm reported net income of close to $15.8 billion for the year. This resulted in a net margin of approximately 33.1%. A net margin measures how much profit a company keeps for every dollar of sales generated after all expenses are paid.

As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 0.7x. This metric compares total liabilities to shareholder equity to assess financial leverage. The current ratio, which measures the ability to pay short-term obligations with short-term assets, sits at approximately 0.8x. For the fiscal year, free cash flow was nearly $4.5 billion. Free cash flow is the cash a business generates after paying for its operations and capital expenditures.

The case for Regeneron Pharmaceuticals

Regeneron Pharmaceuticals focuses on inventing and commercializing medicines for serious conditions, including eye diseases and rare genetic disorders. The company relies on a concentrated group of distributor customers, with two entities accounting for roughly 77% of gross product revenue in 2025. Customer concentration like this adds a layer of risk to the business. To manage its global presence, the firm maintains strategic partnerships with Sanofi (NASDAQ:SNY) and Bayer for its lead products. In July 2026, it expanded its pipeline by collaborating with Telix Pharmaceuticals (NASDAQ:TLX) for cancer therapies.

In FY 2025, revenue reached approximately $14.3 billion, which was a 1% increase over the previous fiscal year. It reported net income of nearly $4.5 billion for the period. This produced a net margin of roughly 31.4%, showing that the company retains nearly a third of its revenue as profit. The company has maintained steady profitability despite facing increased competition in its core therapeutic areas.

As of its December 2025 balance sheet, the debt-to-equity ratio is close to 0.1x, indicating a very low level of total debt relative to equity. The current ratio stands at approximately 4.1x, suggesting a high degree of liquidity for meeting short-term debts. For the fiscal year, free cash flow was nearly $4.1 billion. This represents the actual cash available to the company after it has funded its ongoing operations and necessary equipment purchases.

Risk profile comparison

Novo Nordisk faces risks primarily associated with its heavy reliance on the metabolic health market. As competition in the GLP-1 space intensifies from rivals like Amgen (NASDAQ:AMGN) and AstraZeneca (NYSE:AZN), pricing pressures could impact future growth. Additionally, the company must manage complex global supply chains to meet the soaring demand for its injectable treatments. Regulatory shifts in drug pricing, particularly in the United States, also pose a continuous threat to its high net margins.

Regeneron faces significant revenue concentration, as it is highly dependent on sales of EYLEA and Dupixent. Biosimilar competition began impacting EYLEA sales following the expiration of its U.S. regulatory exclusivity in May 2024. The company is also navigating multiple securities fraud class action lawsuits alleging that investors were misled about clinical trial risks. Furthermore, Regeneron relies heavily on Sanofi and Bayer for commercialization, and any disputes with these partners could disrupt operations. Regulatory delays for candidates like itepekimab also present hurdles to its product pipeline.

Valuation comparison

Regeneron appears to trade at a slight premium based on its P/S ratio, while Novo Nordisk offers a lower multiple relative to its Forward P/E and future earnings estimates.

Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with Regeneron. Its most recent quarter was one of the strongest in the company's history, with every major drug hitting record sales simultaneously. Dupixent grew at an extraordinary pace across all nine of its approved uses, EYLEA HD surpassed its older predecessor in U.S. sales for the first time, and Libtayo posted record global revenue. The company beat earnings estimates by a wide margin and is entering the second half of the year with a step-up in collaboration revenue from its Sanofi partnership. That is a business firing across every product line at once.

Novo Nordisk is not without its strengths. The Wegovy pill captured the vast majority of the U.S. oral obesity market since launch, treating more patients than ever before, and the company raised its full-year outlook. But pricing pressure from the U.S. government, reduced Medicaid coverage for obesity drugs, and intensifying competition from Eli Lilly are creating headwinds that are expected to weigh on results through the rest of the year.

For investors with patience and a long horizon, Regeneron's diversified, multi-drug growth story is a more comfortable foundation than a company navigating significant pricing and competitive pressure on its most important product.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen, AstraZeneca Plc, Eli Lilly, Novo Nordisk, Regeneron Pharmaceuticals, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy.